Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients

Acta Oncol. 2017 Jul;56(7):1023-1026. doi: 10.1080/0284186X.2016.1278459. Epub 2017 Jan 19.

Authors

J J M Kwakman¹, A Baars², H Boot³, J F M Pruijt⁴, S B Winther⁵, P Pfeiffer⁵, C J A Punt¹

Affiliations

¹ a Department of Medical Oncology , Academic Medical Center, University of Amsterdam , Amsterdam , The Netherlands.
² b Department of Medical Oncology , Hospital Gelderse Vallei , Ede , The Netherlands.
³ c Department of Gastroenterology and Hepatology , The Netherlands Cancer Institute , Amsterdam , The Netherlands.
⁴ d Department of Medical Oncology , Jeroen Bosch Hospital , Den Bosch , The Netherlands.
⁵ e Department of Medical Oncology , Odense University Hospital , Odense , Denmark.

PMID: 28102094
DOI: 10.1080/0284186X.2016.1278459

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Capecitabine / adverse effects*
Denmark / epidemiology
Drug Combinations
Drug Substitution* / adverse effects
Drug Substitution* / methods
Female
Hand-Foot Syndrome* / diagnosis
Hand-Foot Syndrome* / prevention & control
Humans
Male
Middle Aged
Neoplasms / drug therapy*
Neoplasms / mortality
Netherlands / epidemiology
Oxonic Acid / administration & dosage*
Oxonic Acid / adverse effects*
Retrospective Studies
Tegafur / administration & dosage*
Tegafur / adverse effects*
Treatment Outcome
Western World

Substances

Drug Combinations
S 1 (combination)
Tegafur
Oxonic Acid
Capecitabine